Cargando…

Left-side vs. right-side hepatectomy for hilar cholangiocarcinoma: a meta-analysis

GOALS: We aim to draw a conclusion which type of hepatectomy could be the priority for hilar cholangiocarcinoma patients. BACKGROUND: Surgery is established as only potentially curative treatment for hilar cholangiocarcinoma. However, whether hepatectomy should be preferred to the left-side hepatect...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Wenxuan, Cheng, Qiyang, Chen, Junru, Chen, Diyu, Feng, Xiaode, Wu, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037893/
https://www.ncbi.nlm.nih.gov/pubmed/33838682
http://dx.doi.org/10.1186/s12957-021-02213-6
_version_ 1783677249942192128
author Wu, Wenxuan
Cheng, Qiyang
Chen, Junru
Chen, Diyu
Feng, Xiaode
Wu, Jian
author_facet Wu, Wenxuan
Cheng, Qiyang
Chen, Junru
Chen, Diyu
Feng, Xiaode
Wu, Jian
author_sort Wu, Wenxuan
collection PubMed
description GOALS: We aim to draw a conclusion which type of hepatectomy could be the priority for hilar cholangiocarcinoma patients. BACKGROUND: Surgery is established as only potentially curative treatment for hilar cholangiocarcinoma. However, whether hepatectomy should be preferred to the left-side hepatectomy, which includes left hemihepatectomy, extended left hemihepatectomy, and left trisectionectomy, or right-side hepatectomy, which represents right hemihepatectomy, extended right hemihepatectomy, and right trisectionectomy, is debated. In this meta-analysis, we evaluated and compared the efficacy and safety of left-side hepatectomy and right-side hepatectomy in patients with hilar cholangiocarcinoma. STUDY: We systematically retrieved the MEDLINE, PubMed, and Cochrane library and related bibliography up to February 2020. The primary outcome is overall survival, and the secondary outcome includes 1-, 3-, and 5-year survival rates, morbidity, mortality, R0 resection rate, and operation time. Based on heterogeneity, fixed-effects model or random-effects models were established through meta-analysis. RESULTS: Eleven studies (11 cohort studies, totally 1031 patients) were involved in this study. The overall survival of patients who underwent left-side hepatectomy was comparable to that of patients who underwent right-side hepatectomy (hazard ratio, 1.27 [95% confidence interval, 0.98–1.63]). And there was no significant difference observed in 1-year (relative risk, 1.01 [95% CI, 0.89–1.15]), 3-year (relative risk, 0.94 [95% confidence interval, 0.80–1.11]), and 5-year survival (relative risk, 0.82 [95% confidence interval, 0.67–1.01]) rates between the left-side hepatectomy group and the right-side hepatectomy group. Comparing with the right-side hepatectomy cluster, the hilar cholangiocarcinoma patients in the left-side hepatectomy cluster presented better overall postoperative morbidity (relative risk, 0.82 [95% confidence interval, 0.71–0.96]) and major postoperative morbidity (relative risk, 0.73 [95% confidence interval, 0.56–0.95]). The post-hepatectomy liver failure rate (relative risk, 0.22 [95% confidence interval, 0.09–0.56]) and procedure-related mortality (relative risk, 0.41 [95% confidence interval, 0.23–0.70]) in the left-side hepatectomy group were better than those of the right-side hepatectomy group. Besides, the R0 resection rate was similar between the left-side hepatectomy group and the right-side hepatectomy group (relative risk, 0.95 [95% confidence interval, 0.87–1.03]). And the operation time for the left-side hepatectomy was significantly longer than that for the right-side hepatectomy (mean difference, 38.68 [95% confidence interval, 7.41–69.95]). CONCLUSION: Through meta-analysis, we explored the comparable long-term outcomes and better short-term outcomes in the left-side hepatectomy group as is compared to the right-side hepatectomy group of hilar cholangiocarcinoma patients. In this study, the evidence obtained might indicate that the choice of left-side hepatectomy or right-side hepatectomy depends on the site of hilar cholangiocarcinoma in every patient. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12957-021-02213-6.
format Online
Article
Text
id pubmed-8037893
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80378932021-04-12 Left-side vs. right-side hepatectomy for hilar cholangiocarcinoma: a meta-analysis Wu, Wenxuan Cheng, Qiyang Chen, Junru Chen, Diyu Feng, Xiaode Wu, Jian World J Surg Oncol Research GOALS: We aim to draw a conclusion which type of hepatectomy could be the priority for hilar cholangiocarcinoma patients. BACKGROUND: Surgery is established as only potentially curative treatment for hilar cholangiocarcinoma. However, whether hepatectomy should be preferred to the left-side hepatectomy, which includes left hemihepatectomy, extended left hemihepatectomy, and left trisectionectomy, or right-side hepatectomy, which represents right hemihepatectomy, extended right hemihepatectomy, and right trisectionectomy, is debated. In this meta-analysis, we evaluated and compared the efficacy and safety of left-side hepatectomy and right-side hepatectomy in patients with hilar cholangiocarcinoma. STUDY: We systematically retrieved the MEDLINE, PubMed, and Cochrane library and related bibliography up to February 2020. The primary outcome is overall survival, and the secondary outcome includes 1-, 3-, and 5-year survival rates, morbidity, mortality, R0 resection rate, and operation time. Based on heterogeneity, fixed-effects model or random-effects models were established through meta-analysis. RESULTS: Eleven studies (11 cohort studies, totally 1031 patients) were involved in this study. The overall survival of patients who underwent left-side hepatectomy was comparable to that of patients who underwent right-side hepatectomy (hazard ratio, 1.27 [95% confidence interval, 0.98–1.63]). And there was no significant difference observed in 1-year (relative risk, 1.01 [95% CI, 0.89–1.15]), 3-year (relative risk, 0.94 [95% confidence interval, 0.80–1.11]), and 5-year survival (relative risk, 0.82 [95% confidence interval, 0.67–1.01]) rates between the left-side hepatectomy group and the right-side hepatectomy group. Comparing with the right-side hepatectomy cluster, the hilar cholangiocarcinoma patients in the left-side hepatectomy cluster presented better overall postoperative morbidity (relative risk, 0.82 [95% confidence interval, 0.71–0.96]) and major postoperative morbidity (relative risk, 0.73 [95% confidence interval, 0.56–0.95]). The post-hepatectomy liver failure rate (relative risk, 0.22 [95% confidence interval, 0.09–0.56]) and procedure-related mortality (relative risk, 0.41 [95% confidence interval, 0.23–0.70]) in the left-side hepatectomy group were better than those of the right-side hepatectomy group. Besides, the R0 resection rate was similar between the left-side hepatectomy group and the right-side hepatectomy group (relative risk, 0.95 [95% confidence interval, 0.87–1.03]). And the operation time for the left-side hepatectomy was significantly longer than that for the right-side hepatectomy (mean difference, 38.68 [95% confidence interval, 7.41–69.95]). CONCLUSION: Through meta-analysis, we explored the comparable long-term outcomes and better short-term outcomes in the left-side hepatectomy group as is compared to the right-side hepatectomy group of hilar cholangiocarcinoma patients. In this study, the evidence obtained might indicate that the choice of left-side hepatectomy or right-side hepatectomy depends on the site of hilar cholangiocarcinoma in every patient. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12957-021-02213-6. BioMed Central 2021-04-10 /pmc/articles/PMC8037893/ /pubmed/33838682 http://dx.doi.org/10.1186/s12957-021-02213-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wu, Wenxuan
Cheng, Qiyang
Chen, Junru
Chen, Diyu
Feng, Xiaode
Wu, Jian
Left-side vs. right-side hepatectomy for hilar cholangiocarcinoma: a meta-analysis
title Left-side vs. right-side hepatectomy for hilar cholangiocarcinoma: a meta-analysis
title_full Left-side vs. right-side hepatectomy for hilar cholangiocarcinoma: a meta-analysis
title_fullStr Left-side vs. right-side hepatectomy for hilar cholangiocarcinoma: a meta-analysis
title_full_unstemmed Left-side vs. right-side hepatectomy for hilar cholangiocarcinoma: a meta-analysis
title_short Left-side vs. right-side hepatectomy for hilar cholangiocarcinoma: a meta-analysis
title_sort left-side vs. right-side hepatectomy for hilar cholangiocarcinoma: a meta-analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037893/
https://www.ncbi.nlm.nih.gov/pubmed/33838682
http://dx.doi.org/10.1186/s12957-021-02213-6
work_keys_str_mv AT wuwenxuan leftsidevsrightsidehepatectomyforhilarcholangiocarcinomaametaanalysis
AT chengqiyang leftsidevsrightsidehepatectomyforhilarcholangiocarcinomaametaanalysis
AT chenjunru leftsidevsrightsidehepatectomyforhilarcholangiocarcinomaametaanalysis
AT chendiyu leftsidevsrightsidehepatectomyforhilarcholangiocarcinomaametaanalysis
AT fengxiaode leftsidevsrightsidehepatectomyforhilarcholangiocarcinomaametaanalysis
AT wujian leftsidevsrightsidehepatectomyforhilarcholangiocarcinomaametaanalysis